Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients

AIDS

Volumn 20, Issue 4, 2006, Pages 567-574

  Mologni, Daniela ^a   Citterio, Paola ^a   Menzaghi, Barbara ^a   Poma, Barbara Zanone ^a   Riva, Chiara ^a   Broggini, Valentina ^a   Sinicco, Alessandro ^c   Milazzo, Laura ^a   Adorni, Fulvio ^b   Rusconi, Stefano ^a   Galli, Massimo ^a   Riva, Agostino ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Antiretroviral therapy; Disease progression; HIV phylogenesis; Long term non progressors; Resistance genotyping; Vpr

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; VPR PROTEIN; ZALCITABINE; ZIDOVUDINE;

ADULT; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; STRUCTURAL GENE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; COMPARATIVE STUDY; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MUTATION; RANDOMIZATION; REGULATOR GENE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; GENES, POL; GENES, VPR; GENOTYPE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MALE; MUTATION; RANDOM ALLOCATION; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 33645419106     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000210611.60459.0e     Document Type: Article

References (55)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
2. Buchbinder S, Vittinghoff E. HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes Infect 1999; 13:1113-1120.
3. Cao J, Park IW, Cooper A, Sodroski J. Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J Virol 1996; 70:1340-1354.
4. LaBonte JA, Patel T, Hofmann W, Sodroski J. Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. J Virol 2000; 74:10690-10698.
5. Lifson JD, Feinberg MD, Reynes GR, Rabin L, Banapour B, Chakrabarti BS, et al. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature 1986; 323:725-728.
6. Roshal M, Zhu Y, Planelles V. Apoptosis in AIDS. Apoptosis 2001; 6:103-116.
7. Xu XN, Laffert B, Screaton GR, Kraft M, Wolf D, Kolanus W, et al. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J Exp Med 1999; 189:1489-1496.
8. Connor RI, Sheridan KE, Lai C, Zhang L, Ho DD. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1996; 70:5306-5311.
9. Michael NL, Chang G, d'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, et al. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol 1995; 69:4228-4236.
10. Morellet N, Bouaziz S, Petitjean P, Roques BP. NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol 2003; 327:215-227.
11. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998; 280:1880-1884.
12. Frankel AD, Young JAT. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998; 67:1-25.
13. Bukrinsky M, Adzhubei A. Viral protein R of HIV-1. Rev Med Virol 1999; 9:39-49.
14. Stewart SA, Poon B, Song JY, Chen ISY. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000; 74:3105-3111.
15. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995; 206:935-944.
16. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91:7311-7315.
17. Popov S, Rexach M, Zybarth G, Reiling N, Lee MA, Ratner L, et al. Viral protein R regulates nuclear import of the HIV-1 preintegration complex. EMBO J 1998; 17:909-917.
18. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 1992; 89:6580-6584.
19. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nature Med 1998; 4:65-71.
20. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R Vpr arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995; 69:6705-6711.
21. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995; 69:6304-6313.
22. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995; 69:6859-6864.
23. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995; 69:882-888.
24. Fouchier RA, Malim MH. Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Advan Virus Res 1999; 52:275-299.
25. Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, et al. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exptl Med 1998; 187:1103-1111.
26. Cullen BR. HIV-1 auxiliary proteins: making connections in a dying cell. Cell 1998; 93:685-692.
27. Singh SP, Lai D, Cartas M, Serio D, Murali R, Kalyanaraman VS, et al. Epitope-tagging approach to determine the stoichiometry of the structural and nonstructural proteins in the virus particles: amount of Vpr in relation to Gag in HIV-1. Virology 2000; 268:364-371.
28. Levy DN, Refaeli Y, MacGregor BR, Weiner DB. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994; 91:10873-10877.
29. Lu YL, Spearman P, Ratner L. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 1993; 67:6542-6550.
30. Arunagiri C, Macreadie I, Hewhish D, Azadi A. A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes. Apoptosis 1997; 2:69-76.
31. Kichler A, Pages JC, Leborgne C, Druillenec S, Lenoir C, Coulaud D, et al. Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R. J Virol 2000; 74:5424-5431.
32. Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HLA, Zamzami N, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000; 191:33-45.
33. Macreadie IG, Castelli LA, Hewish DR, Kirkpatrick A, Ward AC, Azad AA. A domain of human immunodeficiency virus type 1 Vpr containing repeated H S/F RIG amino acid motifs causes cell growth arrest and structural defects. Proc Natl Acad Sci USA 1995; 92:2770-2774.
34. Macreadie IG, Thorburn DR, Kirby DM, Castelli LA, Derozario NL, Azad AA. HIV-1 protein Vpr causes gross mitochondrial dysfunction in the yeast Saccharomyces cerevisiae. FEBS Lett 1997; 410:145-149.
35. Muthumani K, Montaner LJ, Ayyavoo V, Weine DB. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1 Vpr function in macrophages and T-cells. DNA Cell Biol 2000; 19:179-188.
36. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez T, Yao XJ, et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003; 111:1547-1554.
37. Rodés B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, et al. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004; 18:1109-1116.
38. Felsenstein J. PHYLIP: Phylogeny Inference Package, version 3.52. Seattle, WA: University of Washington; 1996.
39. Cavert W, Webb CH, Balfour HH Jr. Alterations in the C-terminal region of the HIV-1 accessory gene vpr do not confer clinical advantage to subjects receiving nucleoside antiretroviral therapy. J Infect Dis 2004; 189:2181-2184.
40. Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, Letourneur F, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004; 18:447-457.
41. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9:415-421.
42. Wang B, Ge YC, Palasanthiran P, Xiang SH, Ziegler J, Dwyer DE, et al. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology 1996; 223:224-232.
43. Somasundaran M, Sharkey M, Brichacek B, Luzuriaga K, Emerman M, Sullivan JL, et al. Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci USA 2002; 99:9503-9508.
44. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. J Exp Med 2001; 193:509-520.
45. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997; 18:44-51.
46. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
47. Lemasters JJ, Nieminen AL, Qjan T, Trost LC, Elmore SP, Nishimura Y, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366:177-196.
48. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283:1482-1488.
49. Vander Heiden MC, Thompson CB. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1999; 1:E209-E216.
50. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13:1899-1911.
51. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6:513-519.
52. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
53. Wei X, Liang C, Gotte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 2002; 16:2391-2398.
54. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003; 311:202-212.
55. Fischer A, Lejczak C, Lambert C, Roman F, Servais J, Karita E, et al. Is the Vpr R77Q mutation associated with long-term non-progression of HIV infection? AIDS 2004; 18:1346-1347.